Skip to content

Endocrine, Cardiovascular, Pharmacological, and Physiological Aspects of Sex Hormone Therapy in Turner Syndrome - Study 2

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518001-18-00
Enrollment
100
Registered
2024-10-08
Start date
2021-11-29
Completion date
Unknown
Last updated
2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Turner syndrome

Brief summary

Body composition: measured by bio impedance, Blood test values: changes in the blood test values from baseline within the areas of metabolism, endocrinology, cardiovascular function, and coagulation, Cardiovascular status: 24-hour ambulatory blood pressure monitoring and arterial stiffness (measured by SphygmoCor), Muscle quality: MR scan of both quadriceps measuring muscle cross-sectional area (CSA) and fat content of the muscle. Maximal isometric muscle strength of both quadriceps (functional muscle tests). Muscle quality = maximum quadriceps strength measured in nM/muscle CSA., Quadriceps strength test: maximal isometric muscle strength of both quadriceps measured simultaneously, Isometric hand strength test: maximal hand strength measured in kilograms, Fitness: maximal oxygen uptake measured by a VO2max test, Bones: bone mineral density as measured by a DEXA scan, Jumping heigth: maximal jumping heigth measured in centimeters

Detailed description

Self-reported health-related quality of life and functioning (SF-36), Self-reported quality of life (WHOQoL-Bref), Subjective assesment of the medication after 6 months of oral and six months of transdermal treatment

Interventions

Sponsors

Region Midtjylland, Region Midtjylland
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Body composition: measured by bio impedance, Blood test values: changes in the blood test values from baseline within the areas of metabolism, endocrinology, cardiovascular function, and coagulation, Cardiovascular status: 24-hour ambulatory blood pressure monitoring and arterial stiffness (measured by SphygmoCor), Muscle quality: MR scan of both quadriceps measuring muscle cross-sectional area (CSA) and fat content of the muscle. Maximal isometric muscle strength of both quadriceps (functional muscle tests). Muscle quality = maximum quadriceps strength measured in nM/muscle CSA., Quadriceps strength test: maximal isometric muscle strength of both quadriceps measured simultaneously, Isometric hand strength test: maximal hand strength measured in kilograms, Fitness: maximal oxygen uptake measured by a VO2max test, Bones: bone mineral density as measured by a DEXA scan, Jumping heigth: maximal jumping heigth measured in centimeters

Secondary

MeasureTime frame
Self-reported health-related quality of life and functioning (SF-36), Self-reported quality of life (WHOQoL-Bref), Subjective assesment of the medication after 6 months of oral and six months of transdermal treatment

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026